Table 5.
Share and range of reported ADRs by therapeutic group (ATC level 1)
| References | [14] | [15] | [16] | [17] | [18] | [19] | [20] | [21] | [22] | [23] | [24] | [25] | [26] | [27] | [28] | [29] | [30] | [31] | [32] | [33] | [34] | [35] | [36] | [37] | [38] | [39] | [40] | [41] | [42] | [43] | [44] | [45] | [46] | Range |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATC groups | ||||||||||||||||||||||||||||||||||
| Alimentary tract and metabolism (A) | – | – | – | – | – | 9 | – | – | – | 2 | – | – | – | – | – | – | – | – | NA | – | – | – | – | 4 | – | – | 10 | – | – | 8 | – | NA | 2 | 2–10 |
| Blood and blood-forming organs (B) | – | – | – | – | – | – | – | – | – | 1 | – | – | – | – | – | – | – | – | NA | 24 | – | – | – | – | – | – | – | – | – | – | – | NA | <1 | 1–24 |
| Cardiovascular systems (C) | – | – | 8 | – | 11 | – | 7 | 29 | – | 5 | – | – | – | – | – | – | – | 20 | NA | – | – | – | – | – | – | – | – | – | – | – | – | NA | <1 | <1–29 |
| Dermatological (D) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 10 | – | NA | – | – | – | – | – | – | – | – | – | – | – | – | NA | 2 | 2–10 |
| Genitourinary system and sex hormones (G) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | NA | – | – | – | – | – | – | – | – | – | – | – | – | NA | 2 | 2 |
| Systemic hormonal preparations (H) | 11 | 8 | – | – | – | – | – | – | – | 5 | – | – | – | 15 | – | – | – | 10 | NA | – | – | – | – | – | – | – | – | – | – | – | – | NA | <1 | <1–11 |
| Anti-infectives for systemic use (J) | 9 | 14 | 41 | 20 | 8 | 45 | 22 | 32 | 29 | 83 | 33 | 76 | 13 | 33 | 27 | 25 | 20 | NA | 24 | 74 | 78 | 67 | 78 | 55 | 16 | 53 | 9 | 25 | 14 | 74 | NA | 65 | 9–83 | |
| Antineoplastic and immunomodulating agents (L) | 8 | 67 | 27 | – | – | – | – | – | 16 | 12 | – | 10 | – | 37 | – | – | – | – | NA | 12 | – | – | – | – | – | – | – | 34 | – | – | – | NA | 2 | 8–67 |
| Musculoskeletal system (M) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | NA | – | – | – | – | – | – | – | – | 5 | 18 | – | – | NA | 1 | 1–18 |
| Nervous system (N) | – | 3 | 16 | 35 | 9 | 11 | 24 | 26 | 24 | 25 | – | 33 | – | 16 | – | 33 | 15 | 30 | NA | 18 | – | – | – | – | – | 7 | – | 6 | – | 20 | 3 | NA | 17 | 3–35 |
| Antiparasitic products (P) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | NA | – | – | – | – | – | – | – | – | – | – | – | – | NA | 1 | 1 |
| Respiratory system (R) | – | – | 8 | 18 | 11 | 17 | 15 | – | 25 | 1 | 15 | – | – | – | – | – | 35 | 20 | NA | 18 | – | – | 7 | 11 | – | – | 22 | – | 26 | 31 | – | NA | 2 | 1–35 |
| Sensory organs (S) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | NA | 4 | – | – | – | – | – | – | – | – | – | – | – | NA | <1 | <1–4 |
| Various (V) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | NA | – | – | – | – | – | – | – | – | – | – | – | – | NA | 3 | 3 |
| Medicines not specified | 72 | 22 | 27 | 6 | 49 | 54 | 9 | 23 | – | 20 | 2 | 19 | 24 | 19 | 67 | 40 | 15 | – | NA | – | 26 | 22 | 26 | 7 | 45 | 77 | 1 | 46 | 33 | 27 | 23 | NA | – | 1–77 |
NA, data not available, no ADRs reported.